Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced $40 million in Series C equity and debt financing. The round was led by Advent Life Sciences. In addition to Gilde Healthcare the round also included returning investors New Enterprise Associates (NEA), Future Fund, Vertex Healthcare, GBS Venture...